New disease-modifying therapies and new challenges for MS

Current Neurology and Neuroscience Reports

Volumn 12, Issue 5, 2012, Pages 489-491

  Yadav, Vijayshree ^a   Bourdette, Dennis ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Anti JCVantibody; Bradyarrhythmia; Fingolimod; Infection; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARREST; HEART DISEASE; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; LOW RISK POPULATION; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; RISK ASSESSMENT; SUDDEN DEATH; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RISK; SPHINGOSINE;

EID: 84870500802     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0295-2     Document Type: Article

References (21)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
3. Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18:1-11.
4. Biogen Idec communication: PML incidence in patients receiving TYSABRI® (natalizumab); 2012.
5. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143-52.
6. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295-303.
7. Product information: TYSABRI(R) intravenous injection, natalizumab intravenous injection. Elan Pharmaceuticals, Inc. (per manufacturer), South San Francisco, CA; 2012.
8. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012;78:436-7.
9. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742-50.
10. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91-101.
11. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
12. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
13. U.S. Food and Drug Administration. FDA Drug Safety Communication. Safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). 2011 12/20/2011. Available from http://www.fda.gov/Drugs/ DrugSafety/ucm284240.htm.
14. European Medicines Agency: European Medicines Agency starts review of Gilenya (fingolimod). Available from http://www.ema. europa.eu/ema/index.jsp? curl0pages/news-and-events/news/2012/01/news-detail-001425.jsp& mid0WC0b01ac058004d5c1. Accessed May 2012.
15. Espinosa PS, Berger Jr. Delayed fingolimod-associated asystole. Mult Scler. 2011;17:1387-9.
16. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105. (Pubitemid 46990553)
17. Product Information: GILENYA(TM) oral capsules, fingolimod oral capsules. Novartis Pharmaceuticals Corporation (Per Manufacturer), East Hanover, NJ, 2012.
18. U.S. Food and Drug Administration. Gilenya (fingolimod): drug safety communication. safety review of a reported death after the first dose. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm284355.htm. Accessed May 2012.
19. Uccelli A, Ginocchio F, Mancardi GL, et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology. 2011;76:1023-4.
20. Nealon N. Severe multiple sclerosis relapse on fingolimod. 5th Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands; 2011.
21. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology. 2012;78:928-30.